The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients - IHU ICAN – Institut de Cardiométabolisme et Nutrition Accéder directement au contenu
Article Dans Une Revue Frontiers in Pharmacology Année : 2022

The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients

Résumé

Introduction: β-arrestin 1, a protein encoded by ARRB1 involved in receptor signaling, is a potential biomarker for the response to antidepressant drug (ATD) treatment in depression. We examined ARRB1 genetic variants for their association with response following ATD treatment in METADAP, a cohort of 6-month ATD-treated depressed patients. Methods: Patients ( n = 388) were assessed at baseline (M0) and after 1 (M1), 3 (M3), and 6 months (M6) of treatment for Hamilton Depression Rating Scale (HDRS) changes, response, and remission. Whole-gene ARRB1 variants identified from high-throughput sequencing were separated by a minor allele frequency (MAF)≥5%. Frequent variants (i.e., MAF≥5%) annotated by RegulomeDB as likely affecting transcription factor binding were analyzed using mixed-effects models. Rare variants (i.e., MAF<5%) were analyzed using a variant set analysis. Results: The variant set analysis of rare variants was significant in explaining HDRS score changes ( T = 878.9; p = 0.0033) and remission ( T = -1974.1; p = 0.034). Rare variant counts were significant in explaining response ( p = 0.016), remission ( p = 0.022), and HDRS scores at M1 ( p = 0.0021) and M3 ( p =<0.001). rs553664 and rs536852 were significantly associated with the HDRS score (rs553664: p = 0.0055 | rs536852: p = 0.046) and remission (rs553664: p = 0.026 | rs536852: p = 0.012) through their interactions with time. At M6, significantly higher HDRS scores were observed in rs553664 AA homozygotes (13.98 ± 1.06) compared to AG heterozygotes (10.59 ± 0.86; p = 0.014) and in rs536852 GG homozygotes (14.88 ± 1.10) compared to AG heterozygotes (11.26 ± 0.95; p = 0.0061). Significantly lower remitter rates were observed in rs536852 GG homozygotes (8%, n = 56) compared to AG heterozygotes (42%, n = 105) at M6 ( p = 0.0018). Conclusion: Our results suggest ARRB1 variants may influence the response to ATD treatment in depressed patients. Further analysis of functional ARRB1 variants and rare variant burden in other populations would help corroborate our exploratory analysis. β-arrestin 1 and genetic variants of ARRB1 may be useful clinical biomarkers for clinical improvement following ATD treatment in depressed individuals. Clinical Trial Registration: clinicaltrials.gov ; identifier NCT00526383
Fichier principal
Vignette du fichier
fphar-13-974570.pdf (1.69 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
licence : CC BY - Paternité

Dates et versions

hal-04021229 , version 1 (06-06-2023)

Identifiants

Citer

Kenneth Chappell, Abd El Kader Ait Tayeb, Romain Colle, Jérôme Bouligand, Khalil El-Asmar, et al.. The association of ARRB1 polymorphisms with response to antidepressant treatment in depressed patients. Frontiers in Pharmacology, 2022, 13, pp.974570. ⟨10.3389/fphar.2022.974570⟩. ⟨hal-04021229⟩
15 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More